Jianchun Duan

Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics

Baixue Wu, Anqi Zhao, Wenlu Chen, Yuying Zhou et autres

Radiotherapy is a cornerstone of comprehensive cancer treatment, yet its efficacy and toxicity exhibit considerable interindividual variation. Recent evidence highlights the microbiome-the collective genomes and metabolic products of symbiotic microorganisms in a specific environment-as a key bidirectional regulator of radiosensitivity. Radiotherapy can …

cn (code pays fourni par la source)

Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases

Danming He, Yixiang Zhu, Jia Zhong, Hong‐Qing Cai et autres

Background: Patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations frequently develop brain metastases (BM). While KRAS G12C was once considered an undruggable target, the emergence of selective inhibitors has transformed it into a viable therapeutic option. However, effective treatment …

cn, us (code pays fourni par la source)

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial

Jia Zhong, Jianchun Duan, Jian Hong Fang, Kailun Fei et autres

cn, us, Éthiopie (code pays fourni par la source)

Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers

Kailun Fei, Jie Zhao, Jiachen Xu, Jianchun Duan et autres

Predictive biomarkers are urgently needed for first-line immune checkpoint inhibitors plus chemotherapy (ICI-chemo) in advanced non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) reflects tumor burden and immunogenicity, potentially identifyinging of patients suitable for ICI-chemo. In this study, pre- and on …

cn, us (code pays fourni par la source)

Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study

Jin−Ji Yang, Yu Mu, Zhehai Wang, Jianchun Duan et autres

OBJECTIVES: This study aimed to evaluate andamertinib, a selective and irreversible tyrosine kinase inhibitor, in pretreated advanced EGFR exon 20 insertion (ex20ins)-mutant NSCLC. METHODS: In the phase 2, multicenter, single-arm KANNON study (NCT06015503), patients with locally advanced or metastatic NSCLC harboring EGFR …

cn, Éthiopie (code pays fourni par la source)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Yan Sun, Haochen Yang, Qing Xu, XingYa Li et autres

Abstract Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti‐PD‐1 nanobody‐armored mesothelin‐targeting CAR‐T (NAC‐T) cells are developed. Based on the enhanced anti‐tumor activity observed in preclinical …

cn (code pays fourni par la source)

P3.12.48 Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

Yao Yu, Lu Si, Qisen Guo, Yonghui Zhang et autres

cn, hk (code pays fourni par la source)

1953P PLB-1004 in advanced non-small cell lung cancer (NSCLC) with exon 20 insertion mutations (ex20ins): A multicenter, single-arm, phase II study

J-J. Yang, Yi-Long Lung Cancer Wu, Yingchun Zhao, Jianchun Duan et autres

cn (code pays fourni par la source)

WITHDRAWN: 1865P Association between immune-related adverse events and clinical outcomes in non-small cell lung cancer patients treated with chemo-immunotherapy: A post hoc analysis of the phase III choice-01 trial

Jie Wang, Jia Zhong, Zhonghua Wang, Jianchun Duan et autres

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study

Jianchun Duan, Qiang Gao, Zhijie Wang, Jiachen Xu et autres

Although circulating cell-free DNA (cfDNA) methylation has emerged as the mainstream approach in multi-cancer detection blood tests (MCDBTs), the potential of integrating proteins and mutations, to enhance its performance remains unclear. The PROMISE study (NCT04972201) was conducted to investigate the feasibility of …

cn (code pays fourni par la source)

RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations

Hong‐Shuai Li, Chengming Liu, Sufei Zheng, Peng Wu et autres

Preclinical/clinical studies suggest that receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) inhibitors combined with immune checkpoint inhibitors (RLICi) enhance anti-tumor efficacy in lung adenocarcinoma (LUAD), yet mechanisms remain unclear. Our retrospective cohort demonstrates RLICi superiority in Kirsten rat sarcoma viral …

cn, us (code pays fourni par la source)

Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches

Yanrong Guo, Songyan Han, Qinxiang Guo, Jinfang Zhai et autres

Background: Small-cell lung cancer (SCLC) has limited therapeutic options beyond first-line treatment, and the efficacy of PD-1/PD-L1-based immunotherapy in this setting remains uncertain. This study evaluates the efficacy and safety of serplulimab-based immunochemotherapy as a second- or later-line treatment for SCLC. Methods: …

cn (code pays fourni par la source)